Design of a Real-World Observational Study in Previously Untreated and Minimally Treated Hemophilia A Patients: Protect-NOW

Background  The efficacy, safety, and immunogenicity of each of Octapharma's factor VIII (FVIII) products, Nuwiq, octanate, and wilate, have been investigated in previously untreated patients (PUPs) with severe hemophilia A in prospective clinical trials. The aim of the Protect-NOW study is to...

Descripción completa

Detalles Bibliográficos
Autores principales: Oldenburg, Johannes, Halimeh, Susan, Hall, Georgina W., Klamroth, Robert, Vera, Pascual Marco, Jansen, Martina, Mathias, Mary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171993/
https://www.ncbi.nlm.nih.gov/pubmed/37180427
http://dx.doi.org/10.1055/s-0043-1768464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171993/
https://www.ncbi.nlm.nih.gov/pubmed/37180427
http://dx.doi.org/10.1055/s-0043-1768464

Ejemplares similares